Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer

Completed · Phase 2

Conditions studied: Ovarian Cancer, Primary Peritoneal Cavity Cancer

In brief

RATIONALE: Estrogen can stimulate the growth of ovarian cancer cells. Hormone therapy using arzoxifene hydrochloride may fight ovarian or peritoneal cancer by blocking the use of estrogen by the tumor cells. PURPOSE: This phase II trial is studying how well arzoxifene hydrochloride works in treating women with metastatic refractory ovarian cancer or primary peritoneal cancer.

Key facts

Study ID

NCT00003670

Run by

Eli Lilly and Company

Starts

1998-10-01

Expected to finish

2001-01-01

Last updated by the study team

2012-06-07

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Ellis Fischel Cancer Center - Columbia — Columbia, Missouri, United States
• Lineberger Comprehensive Cancer Center, UNC — Chapel Hill, North Carolina, United States
• Abington Memorial Hospital — Abington, Pennsylvania, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.